Group 1 - The core point of the article is that the company, 诺诚健华, has indicated that as of December 20, 2025, the number of A-share shareholders is expected to be approximately 18,100 [1]

Core Viewpoint - Nocera Health (688428) experienced a decline in stock price, closing at 20.92 yuan on January 6, 2026, with a decrease of 2.65% [1]. Group 1: Trading Information Summary - On January 6, the net outflow of main funds was 15.638 million yuan, while retail investors saw a net inflow of 22.5536 million yuan [2][3]. Group 2: Company Announcement Summary - As of December 31, 2025, Nocera Health's total share capital remains unchanged at 25 billion ordinary shares, with no change in the number of issued shares [2][3]. - The company has two equity incentive plans: the 2023 RMB stock incentive plan has 4,531,250 shares remaining to be granted, and the 2024 RMB stock incentive plan has 9,645,200 shares remaining to be granted [2].

Core Viewpoint - Nuo Cheng Jian Hua (688428) reported a closing price of 20.92 yuan on January 6, 2026, reflecting a decline of 2.65% from the previous trading day, with a total market capitalization of 36.916 billion yuan [1] Group 1: Stock Performance - The stock opened at 21.29 yuan, reached a high of 21.5 yuan, and a low of 20.71 yuan on the same day [1] - The trading volume amounted to 202 million yuan, with a turnover rate of 3.59% [1] Group 2: Share Capital Information - As of December 31, 2025, the company's registered capital remained unchanged, with a total share capital of 25 billion ordinary shares, each with a par value of 0.000002 USD [1] - The total number of issued shares has not changed, with 1,496,284,235 shares listed on the Hong Kong Stock Exchange, including 1,493,798,235 issued shares and 2,486,000 treasury shares; the shares listed on the Sci-Tech Innovation Board amount to 268,359,717 [1] - There are two equity incentive plans in place: the 2023 RMB stock incentive plan has 4,531,250 shares remaining to be granted, and the 2024 RMB stock incentive plan has 9,645,200 shares remaining to be granted [1]

Core Viewpoint - The approval of the BCL-2 inhibitor Sotorakra by BeiGene marks a significant advancement in the treatment of hematologic malignancies, with potential implications for the competitive landscape of BCL-2 inhibitors in the market [1][3]. Company Developments - BeiGene's Sotorakra has received approval for two indications: treatment of adult patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL) [1]. - The approval came just eight months after the new drug application was accepted by the NMPA, indicating a rapid development timeline [1]. - Sotorakra is positioned as a next-generation BCL-2 inhibitor, designed to block the BCL-2 protein that aids tumor cell survival, and has shown strong efficacy and specificity in clinical trials [1][2]. Clinical Trial Results - Early clinical trials of Sotorakra combined with Zebutini have demonstrated unprecedented rates of undetectable minimal residual disease in treatment-naive CLL patients [2]. - Recent data from five clinical studies indicate significant clinical benefits for Sotorakra, suggesting its potential as a cornerstone therapy for various B-cell malignancies [2]. Market Landscape - The global BCL-2 inhibitor market is projected to reach $5.2 billion by 2028, with the Chinese market expected to reach 1.4 billion yuan [5]. - The approval of Sotorakra follows the approval of another BCL-2 inhibitor, Lisatoclax, from Ascentage Pharma, indicating a growing presence of Chinese companies in the BCL-2 space [3][5]. - The competitive landscape is intensifying as multiple Chinese pharmaceutical companies, including Innovent Biologics and Zai Lab, are developing BCL-2 inhibitors [3][4]. Financial Performance - BeiGene's Zebutini has become a significant revenue driver, with global sales reaching $1.3 billion in 2023, marking a 129% year-over-year increase [6]. - In the first half of 2025, BeiGene reported a revenue of 17.52 billion yuan, a 46% increase year-over-year, largely driven by Zebutini sales [6][7]. - The company is under pressure to identify the next blockbuster product as Zebutini's growth may slow down in the future [7].

Core Insights - The new National Medical Insurance Drug List will take effect on January 1, 2026, allowing innovative drugs with high clinical value to enter the reimbursement system, significantly reducing the financial burden on patients [1] - The inclusion of the BTK inhibitor, Obutinib, for first-line treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) marks a significant advancement in the treatment landscape, transitioning from second-line to first-line therapy [1][3] - The entry of Obutinib into the National Medical Insurance system signifies recognition of this treatment pathway and positions domestic innovative drugs on par with international competitors [3] Industry Overview - CLL primarily affects the elderly, with a median onset age of 65 in China, and its incidence is rising due to an aging population and improved diagnostic capabilities [2] - Despite a lower incidence rate compared to Western countries, the rapid increase in CLL cases in China presents challenges in treatment accessibility and patient compliance [3] - The introduction of targeted therapies, particularly BTK inhibitors, has revolutionized CLL treatment, moving towards a "chemotherapy-free era" [2][4] Market Dynamics - The global market for BTK inhibitors has reached significant scale, with combined sales of five products totaling approximately $11.1 billion in 2022 [4] - New-generation BTK inhibitors are designed to enhance efficacy and safety, addressing the quality of life for patients requiring long-term treatment [4][5] - Obutinib has shown promising clinical results, with an objective response rate of about 93% and a complete response rate of 21.3% in relapsed/refractory CLL/SLL patients [5][6] Future Directions - The successful integration of BTK inhibitors into first-line treatment protocols is supported by major clinical guidelines, indicating a shift towards more effective treatment strategies [6] - Ongoing research is exploring combination therapies, such as Obutinib with new BCL2 inhibitors, aiming for deeper remission and potentially limited-duration treatments [6]

致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底 ...

中国经济网北京1月6日讯 在刚过去的2025年12月份，平安基金共有12只（各份额分开计算，下 同）基金跌幅超过8%。平安港股通医疗创新精选混合C、平安港股通医疗创新精选混合A以13.52%和 13.48%的跌幅成为该公司旗下的垫底基金。 据悉，平安港股通医疗创新精选混合成立于2025年6月11日，由周思聪和张淼共同管理。周思聪曾 先后担任银华基金管理股份有限公司基金经理、长盛基金管理有限公司基金经理。2023年5月加入平安 基金管理有限公司，先后管理公募基金已经长达11年。而张淼曾历任北京中关村科技控股有限公司投资 管理部研究员、东方基金管理有限责任公司行业研究员，基金经理助理、嘉实基金管理有限公司研究部 副总监。2021年6月加入平安基金，现任权益投资部投资执行总经理、基金经理，累计管理经验也超过 10年。 该基金205年三季度前十大重仓股为诺诚健华、药明合联、康方生物、百济神州、科伦博泰生物、 信达生物、三生制药、中国生物制药、石药集团、联邦制药。 由于医药板块在去年的整体表现不佳，周思聪单独管理的其他多只基金跌幅紧随其后，这些基金分 别为平安医疗健康混合C、平安医疗健康混合A、平安医药精选股票C、平安 ...

Group 1 - The core point of the article highlights that in December 2025, the worst-performing ordinary equity and mixed funds were both managed by Baoying Fund, specifically the Baoying Medical Health Hong Kong-Shenzhen Stock A and C, which reported returns of -13.20% and -13.26% respectively [1] - The Baoying Innovation Medical Mixed Initiation A and C funds also performed poorly, with returns of -14.14% and -14.19%, making them the worst in the mixed fund category [1] - All these funds are themed around the medical sector and are managed by the same fund manager, Yao Yi, who has a background in research and fund management [1] Group 2 - The latest quarterly report indicates that the top ten holdings of the Baoying Medical Health Hong Kong-Shenzhen Stock fund include major companies such as Innovent Biologics, Kelun Pharmaceutical, and others, while the Baoying Innovation Medical Mixed Initiation fund shares many of the same top holdings [1][2] - Notably, several of these top holdings experienced significant declines in December, with the largest holding, Innovent Biologics, dropping by 18.97%, and another major holding, 3SBio, declining by over 22% [2] - The performance metrics of the funds show that the Baoying Innovation Medical Mixed Initiation C has a cumulative net value of 0.8857 and a scale of 0.51 billion, while the A share has a cumulative net value of 0.8886 and a scale of 0.47 billion [3]

Core Viewpoint - Nocera Biopharma's stock price has shown a slight increase of 2.05% recently, but has experienced a decline over the past month, indicating potential volatility in the market [1]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1]. Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%. However, the net profit attributable to shareholders was a loss of 64.41 million yuan, although this represents a 76.61% improvement compared to the previous period [2]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 16,500, marking an 8.66% rise. The average circulating shares per person remained unchanged at 0 [2]. - The top ten circulating shareholders include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some previous shareholders have exited the list [3].